Tag: NASDAQ: VBIV

Business

Vaccines Inc (NASDAQ: VBIV) Announces Preliminary Optimistic Stage 1 Data for Its eVLP Vaccine Contender against COVID-19

VBI Vaccines Inc (NASDAQ: VBIV) today announced constructive Stage 1 data from its Stage 1/2 pilot of the paramount of its enclosed virus-like particle (eVLP) COVID-19 inoculation contenders, VBI-2902a, in healthy grownups age 18-54 years of age. The Stage 1 lot of the ongoing Phase 1/2 revision evaluated one- and […]

Business

VBI Vaccines Inc. (NASDAQ: VBIV) Surges 14.45% Following Fast Track Designation For VBI-1901

VBI Vaccines Inc. (NASDAQ: VBIV) stock gained 14.45% after the company announced that the FDA had granted its VBI-1901 cancer vaccine immunotherapeutic candidate a Fast track Designation for the treatment of recurrent glioblastoma patients with first tumor recurrence. Fast Track Designation speeds up developing and reviewing innovative treatments to cure […]